Cannabis is frequently used as a co-medication by patients with cancer or chronic
inflammatory diseases such as rheumatoid arthritis [1]. Accordingly, it has been shown
that cannabinoids modulate apoptotic signalling, and the activity of pro-inflammatory
factors [2]. The advantages of using whole plant preparations compared to pure cannabinoids,
particularly in terms of less toxic side effects, has also been reported [1]. Traditional
Cannabis preparations (TCPs) such as tinctures (e.g. British pharmacopoeia 1932) may thus combine useful biological effects of cannabinoid
and non-cannabinoid constituents. We therefore tested the ability of TCPs to produce
cytotoxicity in an in vitro (MTT) assay and also to modulate the activation of Nuclear Factor kappa B (NF-κB,
IL-6 reporter gene luciferase assay). Our results showed that TCP toxicity in cancer
cells (HeLa, PC12) increased in proportion with the cannabinoid content of the starting
material and decreasing solvent polarity. The LC15 of Cannabis tinctures were between
100µl/ml for high polar extracts and low cannabinoid content and <0.02µl/ml for lipophilic
extracts of high cannabinoid material. Crude extracts/tinctures had a moderate NF-κB-inhibiting
effect at non-toxic concentrations in HeLaluc cells, whereas fractions thereof (specifically medium polar preparations) either
activated or inhibited NF-κB more effectively at concentrations between 0.2 and 100µg/ml.
1H-NMR fingerprints with suppression of solvent signals reflected those effects distinguishing
between five starting materials and the type extract. The ratio between major cannabinoid
and phenolic constituents in TCPs as relevant marker for cytotoxic and anti-inflammatory
effects is suggested.
Acknowledgements: William Ransom & Son Plc, European commission (grant code COOP-CT-2004–512696).
References: [1] Russo, E., Guy, G.W. (2006) Medical Hypotheses 66: 234–246. [2] Juttler, E. et
al. (2004) Neuropharmacol. 47: 580–592.